Scalper1 News
Specialty drugmaker Akorn (AKRX) Monday reported a Q4 in line with estimates, but it guided 2014 below expectations and shares plummeted 15% in early trading in the stock market today. The company said profit totaled 14 cents a share, up a penny from the year-earlier quarter and identical to consensus. Sales rose 19% to $85 million, a bit above analysts’ $83 million. For the full 2013, sales rose 24% to $318 million while net income climbed 6% to Scalper1 News
Scalper1 News